Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

257
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
257
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

167
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
167
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

149
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
149
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

520
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
520
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

273
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
273

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytochrome C-Dependent Processes of Damage of Atherosclerotic Plaque Membranes Regulated by Anionic Phospholipids Containing Saturated and Unsaturated Fatty Acids.

Bulletin of experimental biology and medicine·2025
Same author

[Historical milestones in the study of pulmonary hypertension].

Terapevticheskii arkhiv·2025
Same author

[Emergency measures in the diagnosis and treatment of chronic forms of ischemic heart disease].

Terapevticheskii arkhiv·2025
Same author

[The Role of the Left Atrium in the Pathogenesis of Heart Failure With Preserved Ejection Fraction].

Kardiologiia·2024
Same author

The Structure of Left Ventricular Relaxation in Case of Ventriculography.

Kardiologiia·2024
Same author

[Laboratory Aspects of Using the Results of NT-Probnp Concentration Immunochemical Determination in the Management of Patients With Heart Failure: Support For Clinical Decision-Making].

Kardiologiia·2024

Related Experiment Video

Updated: Dec 17, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.7K

[Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the

A M Shchinova1, G V Shlevkova1, A Y Filatova1

  • 1National Medical Research Center of Cardiology.

Terapevticheskii Arkhiv
|June 30, 2020
PubMed
Summary

Intensive statin therapy significantly reduced high-sensitivity C-reactive protein (hsCRP) levels, a marker of inflammation, in patients undergoing coronary stenting (CS). This reduction may help predict coronary atherosclerosis progression one year after CS.

Keywords:
LDLatherosclerosiscoronary stentinghigh sensitivity C-reactive proteinhsCRPinflammationlow density lipoproteins

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.1K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.6K

Related Experiment Videos

Last Updated: Dec 17, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.7K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.1K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.6K

Area of Science:

  • Cardiology
  • Biochemistry
  • Preventive Medicine

Background:

  • Inflammation is a key risk factor for coronary atherosclerosis progression post-coronary stenting (CS).
  • Intensive statin treatment is known to reduce high-sensitivity C-reactive protein (hsCRP) levels, an inflammatory marker.

Purpose of the Study:

  • To assess the prognostic value of pre-procedural hsCRP level reduction achieved with intensive statin therapy.
  • To evaluate the association between hsCRP reduction and coronary atherosclerosis progression within one year after CS.

Main Methods:

  • 102 patients with stable angina scheduled for CS were enrolled.
  • Group I received high-dose atorvastatin (80 mg) pre- and post-CS; Group II received standard-dose atorvastatin (20-40 mg).
  • hsCRP levels were measured at baseline, pre-CS, and at 1, 3, 6, and 12 months post-CS. Coronary atherosclerosis progression was assessed via coronary angiography one year after CS.

Main Results:

  • Baseline hsCRP levels were similar between groups.
  • Patients receiving intensive atorvastatin (Group I) showed a significant decrease in hsCRP levels post-treatment.
  • The study aimed to correlate these hsCRP changes with coronary atherosclerosis progression.

Conclusions:

  • Pre-procedural hsCRP reduction through intensive statin therapy may serve as a prognostic indicator.
  • Further analysis is needed to establish the direct link between hsCRP reduction and reduced coronary atherosclerosis progression after CS.